Multiple Myeloma

>

Latest News

Anemia May Not Weaken Benefit of Ruxolitinib for Myelofibrosis
Anemia May Not Weaken Benefit of Ruxolitinib for Myelofibrosis

June 16th 2024

New or worsening anemia may not reduce the clinical benefit derived from ruxolitinib treatment in patients with myelofibrosis.

Lower Basal Inflammation, Tumor Burden Linked to PFS Improvements With Ide-Cel in Myeloma
Lower Basal Inflammation, Tumor Burden Linked to PFS Improvements With Ide-Cel in Myeloma

June 14th 2024

D-VRd After Maintenance Boosts MRD-Negativity Rates in Multiple Myeloma Subset
D-VRd After Maintenance Boosts MRD-Negativity Rates in Multiple Myeloma Subset

June 9th 2024

Belantamab Mafodotin Combo Extends PFS vs Daratumumab in Multiple Myeloma
Belantamab Mafodotin Combo Extends PFS vs Daratumumab in Multiple Myeloma

June 5th 2024

Teclistamab Regimen Provides Early Responses, Manageable Safety in Multiple Myeloma
Teclistamab Regimen Provides Early Responses, Manageable Safety in Multiple Myeloma

June 4th 2024

Video Interviews
Podcasts
The Vitals

More News

© 2024 MJH Life Sciences

All rights reserved.